<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2019.94060</article-id><article-id pub-id-type="publisher-id">ACM-29573</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20190400000_85877176.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  多重打击学说下的IgAN基因多态性的研究进展
  Advances in Research on IgAN Gene Polymorphism under Multiple-Hits Theory
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>徐</surname><given-names>畅</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib></contrib-group><aff id="aff1"><label>1</label><addr-line>null</addr-line></aff><aff id="aff2"><label>1</label><addr-line>大连医科大学，辽宁 大连</addr-line></aff><pub-date pub-type="epub"><day>29</day><month>03</month><year>2019</year></pub-date><volume>09</volume><issue>04</issue><fpage>395</fpage><lpage>400</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    IgA肾病(IgA nephropathy, IgAN)是全世界最常见的原发性肾小球疾病。遗传，免疫，糖基化改变等多重打击导致系膜区IgA1及其免疫复合物沉积，造成系膜细胞的增殖及肾损伤。临床表现多样并多伴有血尿，部分进展为终末期肾脏病。目前，IgAN的发病机制尚不清楚。随着全基因组连锁分析(GWAS)在IgAN的不断应用，遗传因素的致病作用受到越来越多的关注。本文将对GWAS发现的基因及这些基因在多重打击学说下的研究进展加以综述。
    IgA nephropathy (IgAN) is the most common primary glomerulonephritis in the world. Multiple hits such as heredity, immunity and glycosylated changes lead to deposition of IgA1 and its immune complexes in the mesangial area, and result in mesangial cell proliferation and glomerular damage. The clinical manifestations are diverse and often accompanied by hematuria, and some progress to end-stage renal disease. At present, the pathogenesis of IgAN is still unclear. With the continuous application of genome-wide linkage analysis (GWAS) in IgAN, the pathogenic role of genetic factors has received more and more attention. This article will review the genes discovered by GWAS and the research progress of these genes under the multiple-hits theory. 
  
 
</p></abstract><kwd-group><kwd>IgA肾病，全基因组连锁分析，基因多态性，多重打击学说, IgA Nephropathy</kwd><kwd> Genome-Wide Linkage Analysis</kwd><kwd> Gene Polymorphism</kwd><kwd> Multiple-Hits Theory</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>多重打击学说下的IgAN基因多态性的研究进展<sup> </sup></title><p>徐畅</p><p>大连医科大学，辽宁 大连</p><p><img src="//html.hanspub.org/file/3-1570881x1_hanspub.png" /></p><p>收稿日期：2019年3月11日；录用日期：2019年3月26日；发布日期：2019年4月3日</p><disp-formula id="hanspub.29573-formula20"><graphic xlink:href="//html.hanspub.org/file/3-1570881x5_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s2"><title>摘 要</title><p>IgA肾病(IgA nephropathy, IgAN)是全世界最常见的原发性肾小球疾病。遗传，免疫，糖基化改变等多重打击导致系膜区IgA1及其免疫复合物沉积，造成系膜细胞的增殖及肾损伤。临床表现多样并多伴有血尿，部分进展为终末期肾脏病。目前，IgAN的发病机制尚不清楚。随着全基因组连锁分析(GWAS)在IgAN的不断应用，遗传因素的致病作用受到越来越多的关注。本文将对GWAS发现的基因及这些基因在多重打击学说下的研究进展加以综述。</p><p>关键词 :IgA肾病，全基因组连锁分析，基因多态性，多重打击学说</p><disp-formula id="hanspub.29573-formula21"><graphic xlink:href="//html.hanspub.org/file/3-1570881x6_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2019 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/3-1570881x7_hanspub.png" /> <img src="//html.hanspub.org/file/3-1570881x8_hanspub.png" /></p></sec><sec id="s3"><title>1. IgA肾病的多重打击学说</title><p>IgAN作为一类常见的肾小球疾病，占全世界原发性肾小球疾病的首位，发病率在不同地区有所不同，美国IgAN发病率约占原发性肾小球疾病的12.1%，中国IgAN的发病率约占原发性肾小球疾病的37.8%。该病临床症状隐匿，常为镜下血尿也可见肉眼血尿。在此疾病的进程中，血清内多聚的半乳糖缺乏型IgA1 (Galactosed-deficiency IgA1, Gd-IgA1)发挥重要的作用。其中以IgA1为基础的多重打击的学说受到普遍认可，即第一次打击，血清内增多的Gd-IgA1；第二次打击，针对Gd-IgA1铰链区的特异性免疫；第三次打击，免疫复合物的形成及补体和免疫细胞的参与；最终造成第四次打击，系膜细胞的增殖及肾小球滤过率的降低 [<xref ref-type="bibr" rid="hanspub.29573-ref1">1</xref>]。</p></sec><sec id="s4"><title>2. IgA肾病的基因多态性</title>IgA肾病的遗传学证据<p>IgAN的流行在不同地域和种族中表现出相当大的差异 [<xref ref-type="bibr" rid="hanspub.29573-ref2">2</xref>] ，即亚洲人口发病最高，非洲最低 [<xref ref-type="bibr" rid="hanspub.29573-ref3">3</xref>] [<xref ref-type="bibr" rid="hanspub.29573-ref4">4</xref>] [<xref ref-type="bibr" rid="hanspub.29573-ref5">5</xref>]。尽管每个国家的肾活检的指征和技术不同，对地域和种族间差异存在一定影响，但IgAN的遗传因素仍是导致地域和种族间差异的重要原因。此外，IgAN存在一定的家族聚集性 [<xref ref-type="bibr" rid="hanspub.29573-ref6">6</xref>] [<xref ref-type="bibr" rid="hanspub.29573-ref7">7</xref>]。在IgAN家族的研究中，患者被分为散发性(只有一个家庭成员受影响)；疑似家族性(一名成员有活检证实的IgAN，其他人存在尿检异常)；家族性(至少两人有活检证实的IgAN)。研究证明，在欧洲超过50%的IgAN患者患有家族性或疑似家族性的IgAN [<xref ref-type="bibr" rid="hanspub.29573-ref8">8</xref>]。不仅如此，IgAN患者的亲属比一般人群具有更高水平的Gd-IgA1，证明IgA1糖基化是一种遗传而非获得的特征 [<xref ref-type="bibr" rid="hanspub.29573-ref9">9</xref>]。家族性IgAN的较高患病率和较差的预后同样表明遗传因素参与IgAN的发展。</p></sec><sec id="s5"><title>3. IgA肾病的基因多态性</title><sec id="s5_1"><title>3.1. 第一次打击血清内增多的Gd-IgA1</title><p>IgA1糖基修饰相关基因——ST6GAL1</p><p>IgAN中，系膜区以Gd-IgA1沉积为主，其半乳糖的缺乏与其糖基修饰过程密切相关。先前研究证明，IgA1糖基化过程中的C1GalT1及其分子伴侣Cosmc可促进半乳糖与IgA1铰链区糖基链上的N-乙酰半乳糖胺相连 [<xref ref-type="bibr" rid="hanspub.29573-ref10">10</xref>]。且IgAN时，常存在编码Cosmc的基因改变和Cosmc的表达降低，从而引起半乳糖不能连接于IgA1铰链区。故编码C1GalT1及其分子伴侣Cosmc的基因在IgAN的发病机制中发挥重要作用 [<xref ref-type="bibr" rid="hanspub.29573-ref11">11</xref>]。</p><p>近年进一步对汉族人进行的四阶段GWAS，鉴定出新的糖基修饰关键基因：ST6GAL1 (3q27.3) [<xref ref-type="bibr" rid="hanspub.29573-ref12">12</xref>]。ST6GAL1编码ST6-β-半乳糖酰胺α-2,6-唾液酸转移酶，主要负责IgA1铰链区半乳糖的唾液酸化。当Gd-IgA1唾液酸化增加，可通过以下方式导致IgAN的发病：1) 唾液酸的负电荷使Gd-IgA1更具阴离子性，使IgA1及免疫复合物在带正电的系膜区沉积增多；2) 负电荷的大分子唾液酸引起IgA1三级结构、铰链区静电排斥和空间位阻的改变 [<xref ref-type="bibr" rid="hanspub.29573-ref13">13</xref>] ，抗原性增强从而不断堆积，使Gd-IgA1易沉积于系膜区；3) ST6GAL1编码的蛋白作为甘油–甲基转移酶家族成员，可形成细胞表面糖原决定簇和分化抗原，并通过催化TNFR1死亡受体唾液酸化调节巨噬细胞凋亡 [<xref ref-type="bibr" rid="hanspub.29573-ref12">12</xref>]。使得巨噬细胞处理 Gd-IgA1能力下降，导致其异常沉积。</p></sec><sec id="s5_2"><title>3.2. 第二次打击针对Gd-IgA1铰链区的特异性免疫</title><p>IgAN前驱感染相关基因——TNFSF13，HORMAD2，DEFA</p><p>IgAN前驱感染的粘膜病原体与IgA1间相互作用被认为是IgAN第一次和第二次打击的诱因。在感染期间，宿主通过模式识别受体结合并检测病原体；随后宿主启动第一道防线，包括细胞因子表达的诱导，抗微生物蛋白的分泌，以及免疫细胞的募集或活化，以抵抗感染。目前已被检测的GWAS基因常与负责微生物免疫的粘膜异常有关 [<xref ref-type="bibr" rid="hanspub.29573-ref14">14</xref>] [<xref ref-type="bibr" rid="hanspub.29573-ref15">15</xref>]。</p><p>如，肿瘤坏死因子超家族13 (TNFSF13)基因可编码增殖诱导配体(APRIL)，一种肿瘤坏死因子配体，它与粘膜感染的反应和肠道相关粘膜淋巴组织产生的IgA有关。TNFSF13基因变异风险增高与血清中Gd-IgA水平增加密切相关 [<xref ref-type="bibr" rid="hanspub.29573-ref16">16</xref>]。研究显示小鼠TNFSF13的失活可导致血清Gd-IgA1水平显著降低，且高水平的TNFSF13与肾移植后IgA肾病的复发存在联系 [<xref ref-type="bibr" rid="hanspub.29573-ref17">17</xref>]。</p><p>除TNFSF13的作用之外，IgAN的GWAS中的另一信号存在于22q12.2上的HORMAD2。它包括关键基因：myotubularin相关蛋白3 (MTMR3)；含HORMA结构域蛋白2 (HORMAD2)；白血病抑制因子(LIF)；和Oncostatin M (OSM)。LIF和OSM是IL-6相关细胞因子，体外研究表明，IL-6家族细胞因子可以增强Gd-IgA1的产生 [<xref ref-type="bibr" rid="hanspub.29573-ref18">18</xref>]。尽管MTMR3和HORMAD2的功能尚不清楚，但这些基因的SNP可在其他免疫疾病如扁桃体炎和炎症性肠病(IBD)中被发现，这表明这些基因可能通过粘膜免疫增加IgAN风险 [<xref ref-type="bibr" rid="hanspub.29573-ref19">19</xref>]。</p><p>DEFA基因簇编码防御素家族，是先天性和适应性免疫中的重要效应分子。人类防御素家族分为α和β。α-防御素主要在中性粒细胞和肠道的细胞中表达，参与维持肠粘膜屏障并调节粘膜免疫应答 [<xref ref-type="bibr" rid="hanspub.29573-ref20">20</xref>]。研究发现，DEFA基因的总拷贝数变异(包括DEFA1A3，DEFA3)与IgAN的易感性和进展强烈相关 [<xref ref-type="bibr" rid="hanspub.29573-ref21">21</xref>]。在IgAN患者的血清和尿液样品中，DEFA1A3在中性粒细胞表达的蛋白质产物，中性粒细胞肽1-3 (HNP1-3)的表达增加。同样当正常个体受脂多糖刺激时，来自健康的中性粒细胞产生的HNP1-3比IgAN患者产生的HNP1-3更多。这些结果表明在IgAN患者中DEFA1A3的表达或功能存在缺陷 [<xref ref-type="bibr" rid="hanspub.29573-ref22">22</xref>]。</p><p>总之，这些遗传证据表明宿主和肠道病原体之间的相互作用在IgAN中发挥重要作用。二者的相互作用激活黏膜免疫系统，并促进特异性免疫过度活化，产生异常的Gd-IgA1。</p></sec><sec id="s5_3"><title>3.3. 第三次打击免疫复合物的形成及补体和免疫细胞的参与</title><p>IgAN患者的Gd-IgA1与其特异性抗体形成免疫复合物后，沉积于系膜区。沉积的免疫复合物常激活补体和免疫细胞，造成系膜细胞的损伤。血清中常可见补体C3和备解素，并经常检测到C4或C4d、甘露糖结合凝集素、和末端补体复合物(C5b-C9)，而C1q通常不存在。这些发现表明补体的替代途径和凝集素途径在IgAN中起到重要作用 [<xref ref-type="bibr" rid="hanspub.29573-ref11">11</xref>]。</p><p>IgAN免疫激活相关基因——CFHR，TNFSF13，ITGAX-ITGAM，VAV3和CARD9</p><p>IgAN的GWAS分析显示在1q32染色体处存在另一个信号，这一区域包含补体因子H (CFH)和相关的CFHR1，CFHR2，CFHR3，CFHR4和CFHR5基因。CFH蛋白作为补体激活抑制剂，具有多种功能，包括：竞争因子B结合位点，阻碍C3转化酶的形成，促进C3转化酶的解离，支持C3b蛋白水解切割 [<xref ref-type="bibr" rid="hanspub.29573-ref23">23</xref>]。这段染色体区域中最显着的SNP是rs6677604 [<xref ref-type="bibr" rid="hanspub.29573-ref24">24</xref>]。其A等位基因具有保护作用，并编码CFHR3-1D。CFHR3-1D可导致CFHR1-3缺失 [<xref ref-type="bibr" rid="hanspub.29573-ref25">25</xref>]。早期的研究发现，CFH的等位基因CFHR1和CFHR3基因，作为替代补体途径中两个关键的CFH相关参与者，在IgAN中常共同缺失 [<xref ref-type="bibr" rid="hanspub.29573-ref12">12</xref>]。</p><p>通过对IgAN家庭进行两阶段全基因组连锁分析，发现TNFSF13同样参与IgAN肾病免疫激活过程 [<xref ref-type="bibr" rid="hanspub.29573-ref26">26</xref>]。TNFSF13编码的增殖诱导配体(APRIL)，可与TNF受体家族的细胞表面受体识别，对B细胞发育起到关键作用，促进产生分泌IgA的浆细胞，完成IgA1至IgA2类转换 [<xref ref-type="bibr" rid="hanspub.29573-ref27">27</xref>]。这些结果表明TNFSF13可能与IgAN中IgA1的产生和粘膜免疫有关。</p><p>Kiryluk等在IgAN中发现ITGAM-ITGAX，VAV3和CARD9新的全基因组关联 [<xref ref-type="bibr" rid="hanspub.29573-ref15">15</xref>]。这三个区域内的最显著的SNP分别为rs11574637，rs11150612，rs17019602。ITGAX-ITGAM编码白细胞特异性整合素，参与白细胞粘附，迁移，单核细胞和巨噬细胞补体包被，吞噬细胞凋亡。VAV3编码鸟嘌呤核苷酸交换因子，其对B和T淋巴细胞发育和抗原呈递十分重要。CARD9编码含有半胱天冬酶募集结构域的蛋白，是一种促进巨噬细胞中核因子NF-κB活化的衔接蛋白。可见这三个基因可从不同方面促进 IgAN 系膜区炎症反应。</p></sec><sec id="s5_4"><title>3.4. 第四次打击系膜细胞的增殖及肾小球滤过率的降低</title><p>系膜细胞的炎症反应在IgAN肾损伤中起重要作用。Gd-IgA1及其免疫复合物可刺激系膜增生和并促进局部产生细胞因子和趋化因子，如IL-6和转化生长因子。此外，HLA-DRB1基因多态性与系膜增生性IgA肾病相关，DRB1-09和DRB1-11类型可增加系膜增生性IgA肾病的风险，并且与患者肾小球肾炎严重程度有关 [<xref ref-type="bibr" rid="hanspub.29573-ref28">28</xref>]。不仅如此，IgAN中存在白细胞募集和肾小球及肾小管间质的纤维化来加重炎症反应，导致系膜细胞进一步增殖 [<xref ref-type="bibr" rid="hanspub.29573-ref1">1</xref>]。</p><p>图1. Iga肾病基因及其功能机制</p></sec></sec><sec id="s6"><title>4. 总结</title><p>多重打击下基因的变化参与Gd-IgA1聚集，Gd-IgA1及其免疫复合物沉积和免疫反应(见图1 Iga肾病基因及其功能机制)，包括微生物抗原，IgG或IgA的复合物，以及系膜细胞外基质蛋白等多种分子。这些含Gd-IgA1的复合物刺激系膜细胞增殖，并引起随后的免疫反应，包括补体的激活和炎症反应的放大，最终造成系膜细胞增殖及肾损伤。虽然GWAS已发现许多易感位点 [<xref ref-type="bibr" rid="hanspub.29573-ref29">29</xref>] ，但各个基因的精确机制仍不了解，且几种潜在的信号分子，包括转谷氨酰胺酶2和CD71等 [<xref ref-type="bibr" rid="hanspub.29573-ref30">30</xref>] 参与免疫复合物的形成沉积仍需要进一步调查。基因组数据的整合与新遗传分析技术的应用，将明确IgAN临床表型和遗传因素间的关系，更好地了解个体间变异的潜在因素，对长期预后和治疗提出新的解决方案。</p></sec><sec id="s7"><title>文章引用</title><p>徐 畅. 多重打击学说下的IgAN基因多态性的研究进展Advances in Research on IgAN Gene Polymorphism under Multiple-Hits Theory[J]. 临床医学进展, 2019, 09(04): 395-400. https://doi.org/10.12677/ACM.2019.94060</p></sec><sec id="s8"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.29573-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Rodrigues, J.C., Haas, M. and Reich, H.N. (2017) IgA Nephropathy. Clinical Journal of the American Society of Nephrology, 12, 677-686. &lt;br&gt;https://doi.org/10.2215/CJN.07420716</mixed-citation></ref><ref id="hanspub.29573-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Schena, F.P. and Nistor, I. (2018) Epide-miology of IgA Nephropathy: A Global Perspective. Seminars in Nephrology, 38, 435-442. &lt;br&gt;https://doi.org/10.1016/j.semnephrol.2018.05.013</mixed-citation></ref><ref id="hanspub.29573-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Shin, H.S., Cho, D.H., Kang, S.K., et al. (2017) Patterns of Renal Disease in South Korea: A 20-Year Review of a Single-Center Renal Biopsy Database. Renal Failure, 39, 540-546. &lt;br&gt;https://doi.org/10.1080/0886022X.2017.1348955</mixed-citation></ref><ref id="hanspub.29573-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Garnier, A.S., Duveau, A., Demiselle, J., et al. (2018) Early Post-Transplant Serum IgA Level Is Associated with IgA Nephropathy Recurrence after Kidney Transplantation. PLoS ONE, 13, e0196101.</mixed-citation></ref><ref id="hanspub.29573-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Barrera-Herrera, L.E., Lopez Panqueva, R.D.P., Florez Vargas, A.A., et al. (2017) The Spectrum of Glomerular Disease between the Years 2003 and 2015 in Columbia: A Review of 12,613 Cases. Revista Española de Patología, 50, 3-7. &lt;br&gt;https://doi.org/10.1016/j.patol.2016.07.006</mixed-citation></ref><ref id="hanspub.29573-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Paterson, A.D., Liu, X.Q., Wang, K., et al. (2007) Genome-Wide Linkage Scan of a Large Family with IgA Nephropathy Localizes a Novel Susceptibility Locus to Chromosome 2q36. Journal of the American Society of Nephrology, 18, 2408-2415. &lt;br&gt;https://doi.org/10.1681/ASN.2007020241</mixed-citation></ref><ref id="hanspub.29573-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Cox, S.N., Pesce, F., El-Sayed Moustafa, J.S., et al. (2017) Multi-ple Rare Genetic Variants Co-Segregating with Familial IgA Nephropathy All Act within a Single Immune-Related Network. Journal of Internal Medicine, 281, 189-205. &lt;br&gt;https://doi.org/10.1111/joim.12565</mixed-citation></ref><ref id="hanspub.29573-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Schena, F.P., Ce-rullo, G., Rossini, M., et al. (2002) Increased Risk of End-Stage Renal Disease in Familial IgA Nephropathy. Journal of the American Society of Nephrology, 13, 453-460.</mixed-citation></ref><ref id="hanspub.29573-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Lomax-Browne, H.J., Visconti, A., Pusey, C.D., et al. (2017) IgA1 Glycosylation Is Heritable in Healthy Twins. Journal of the American Society of Nephrology, 28, 64-68. &lt;br&gt;https://doi.org/10.1681/ASN.2016020184</mixed-citation></ref><ref id="hanspub.29573-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">黄海, 列才华, 梁兰青, 等. C1GALT1基因变异与IgA肾病遗传易感性的相关性研究[J]. 转化医学杂志, 2018, 7(5): 268-271.</mixed-citation></ref><ref id="hanspub.29573-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Wyatt, R.J. and Julian, B.A. (2013) IgA Nephropathy. New England Journal of Medicine, 368, 2402-2414.  
&lt;br&gt;https://doi.org/10.1056/NEJMra1206793</mixed-citation></ref><ref id="hanspub.29573-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Li, M., Foo, J.N., Wang, J.Q., et al. (2015) Identification of New Susceptibility Loci for IgA Nephropathy in Han Chinese. Nature Communications, 6, 7270.</mixed-citation></ref><ref id="hanspub.29573-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Leung, J.C., Tang, S.C., Lam, M.F., et al. (2001) Charge-Dependent Binding of Polymeric IgA1 to Human Mesangial Cells in IgA Nephropathy. Kidney International, 59, 277-285. &lt;br&gt;https://doi.org/10.1046/j.1523-1755.2001.00489.x</mixed-citation></ref><ref id="hanspub.29573-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Feehally, J., Farrall, M., Boland, A., et al. (2010) HLA Has Strongest Association with IgA Nephropathy in Genome-Wide Analysis. Journal of the American Society of Nephrology, 21, 1791-1797.  
&lt;br&gt;https://doi.org/10.1681/ASN.2010010076</mixed-citation></ref><ref id="hanspub.29573-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Kiryluk, K., Li, Y., Scolari, F., et al. (2014) Discovery of New Risk Loci for IgA Nephropathy Implicates Genes Involved in Immunity against Intestinal Pathogens. Nature Genetics, 46, 1187-1196. &lt;br&gt;https://doi.org/10.1038/ng.3118</mixed-citation></ref><ref id="hanspub.29573-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Kiryluk, K., Novak, J. and Gharavi, A.G. (2013) Pathogenesis of Immunoglobulin A Nephropathy: Recent Insight from Genetic Studies. Annual Review of Medicine, 64, 339-356.</mixed-citation></ref><ref id="hanspub.29573-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Jo, H.A., Han, S.S., Lee, S., et al. (2019) The Association of Tumor Necrosis Factor Superfamily 13 with Recurrence of Immunoglobulin A Nephropathy in Living Related Kidney Transplantation. BMC Nephrology, 20, 33.  
&lt;br&gt;https://doi.org/10.1186/s12882-019-1222-4</mixed-citation></ref><ref id="hanspub.29573-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Silver, J.S. and Hunter, C.A. (2010) gp130 at the Nexus of In-flammation, Autoimmunity, and Cancer. Journal of Leukocyte Biology, 88, 1145-1156. &lt;br&gt;https://doi.org/10.1189/jlb.0410217</mixed-citation></ref><ref id="hanspub.29573-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Knoppers, B.M., Zawati, M.H. and Senecal, K. (2015) Return of Genetic Testing Results in the Era of Whole-Genome Sequencing. Nature Reviews Genetics, 16, 553-559. &lt;br&gt;https://doi.org/10.1038/nrg3960</mixed-citation></ref><ref id="hanspub.29573-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Chu, H., Pazgier, M., Jung, G., et al. (2012) Human Alpha-Defensin 6 Promotes Mucosal Innate Immunity through Self-Assembled Peptide Nanonets. Science, 337, 477-481. &lt;br&gt;https://doi.org/10.1126/science.1218831</mixed-citation></ref><ref id="hanspub.29573-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Ai, Z., Li, M., Liu, W., et al. (2016) Low Alpha-Defensin Gene Copy Number Increases the Risk for IgA Nephropathy and Renal Dysfunction. Science Translational Medicine, 8, 345ra388.</mixed-citation></ref><ref id="hanspub.29573-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Qi, Y.Y., Zhou, X.J., Cheng, F.J., et al. (2016) Elevated Plasma Alpha-Defensins (HNP1-3) Levels Correlated with IgA1 Glycosylation and Susceptibility to IgA Nephropathy. Disease Markers, 2016, 8123138.</mixed-citation></ref><ref id="hanspub.29573-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Goicoechea de Jorge, E., Caesar, J.J., Malik, T.H., et al. (2013) Dimerization of Complement Factor H-Related Proteins Modulates Complement Activation in Vivo. Proceedings of the National Academy of Sciences, 110, 4685-4690.  
&lt;br&gt;https://doi.org/10.1073/pnas.1219260110</mixed-citation></ref><ref id="hanspub.29573-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Gharavi, A.G., Kiryluk, K., Choi, M., et al. (2011) Genome-Wide Association Study Identifies Susceptibility Loci for IgA Nephropathy. Nature Genetics, 43, 321-327. &lt;br&gt;https://doi.org/10.1038/ng.787</mixed-citation></ref><ref id="hanspub.29573-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Zipfel, P.F. (2009) Complement and Immune Defense: From Innate Immunity to Human Diseases. Immunology Letters, 126, 1-7.</mixed-citation></ref><ref id="hanspub.29573-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Bisceglia, L., Cerullo, G., Forabosco, P., et al. (2006) Genetic Heterogeneity in Italian Families with IgA Nephropathy: Suggestive Linkage for Two Novel IgA Nephropathy Loci. American Journal of Human Genetics, 79, 1130-1134.  
&lt;br&gt;https://doi.org/10.1086/510135</mixed-citation></ref><ref id="hanspub.29573-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Shimojima, Y., Kishida, D. and Sekijima, Y. (2017) Increased BAFF and APRIL Levels in the Cerebrospinal Fluid of Patients with Anti-Neutrophil Cytoplasmic Antibody-Related Hypertrophic Pachymeningitis. Cytokine, 99, 305-309.</mixed-citation></ref><ref id="hanspub.29573-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">赖寒, 甘华. 系膜增生性IgA肾病患者HLA-DRB1基因分型的研究[J]. 中国免疫学杂志, 2015, 31(11): 1528-1531.</mixed-citation></ref><ref id="hanspub.29573-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">李明, 余学清. IgA肾病全基因组关联分析研究[J]. 中国实用内科杂志, 2014, 34(3): 220-222.</mixed-citation></ref><ref id="hanspub.29573-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">Berthelot, L., Papista, C., Maciel, T.T., et al. (2012) Transglutaminase Is Essential for IgA Nephropathy Development Acting through IgA Receptors. The Journal of Experimental Medicine, 209, 793-806.  
&lt;br&gt;https://doi.org/10.1084/jem.20112005</mixed-citation></ref></ref-list></back></article>